UNC, Kerr Drug to Study PGx Program for Plavix | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Drug store chain Kerr Drug and the Eshelman School of Pharmacy at the University of North Carolina, Chapel Hill plan to investigate the feasibility of implementing a pharmacogenomic program at the community pharmacy level directed at Plavix (clopidogrel).

Under the six-month study announced today, the partners will jointly develop a protocol, evaluate physician and patients opinions, and research reimbursement challenges and regulatory requirements to such a program.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.